Date:8/17/2012

ny has alliances in which its technologies are integrated with medicinal, combinatorial and computational chemistry, animal models and clinical trials to provide modular or complete services along the drug development pathway. Since its inception in 1998, ChanTest has tested compounds for more than 500 global pharmaceutical and biotechnology companies. ChanTest's library of  ion channel cell lines, validated human stem cell-derived cardiomyocytes and  predictive nonclinical cardiac risk assessment program are  the most comprehensive available today. Because of ChanTest's seminal role in cardiac safety and its uncompromising commitment to quality, ChanTest has been named the "most trusted and most used fee-for-service provider" for ion channel screening in an independent survey for the past three years. ChanTest is based in Cleveland, Ohio. For more information, e-mail info@chantest.com.

CONTACT: Kate Siver, +1-216-332-1665, info@chantest.com

'/>"/>

SOURCE ChanTest Corporation Copyright©2012 PR Newswire. All rights reserved

0 GOOD

Page: 1 2
Related medicine technology :

1. Meridian Labs Hires Investment Bank to Explore Strategic Opportunities
2. Health Revenue Assurance Associates Hires Valerie Rinkle as Vice President of Revenue Integrity Informatics
3. CSS Health Technologies Hires Industry Leader as New Senior Vice President of Sales
4. NHD Hires Ron Cronin as Executive Director
5. Millstone Medical Outsourcing Hires New Vice President Quality
6. Zimmer Holdings Names Christopher Begley to Board of Directors
7. Doug Pepper appointed as Chief Financial Officer at Cardiac Science
8. ADVENTRX Announces Appointment Of Chief Medical Officer
9. Accelr8 Appoints Steve Reichling Chief Financial Officer
10. Nile Therapeutics Promotes Darlene Horton, M.D., to Chief Executive Officer and Director
11. Qforma Chief Technologist Honored as One of PharmaVOICE Magazines "100 Most Inspiring People in the Life Sciences"